Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Percheron Therapeutics ( (AU:PER) ) is now available.
Percheron Therapeutics Limited has released a prospectus for a two-for-five pro rata non-renounceable rights offer, allowing eligible shareholders to subscribe for new shares at $0.005 each, with one new option issued for every two new shares taken up. The document also outlines a shortfall offer and a joint lead manager options offer, with the capital raising framed as speculative and intended to support the company’s future activities, underscoring both the funding needs and risk profile facing existing and prospective investors.
The offers are scheduled to close on 8 April 2026 at 5:00 p.m. AEST, with the company reserving the right to vary the timetable, placing a time-bound decision on shareholders considering participation. By structuring the raising as a pro rata rights issue with additional options, Percheron seeks to balance shareholder dilution with participation opportunities while signalling its continued reliance on equity markets to finance its growth and development plans.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a biotechnology company operating in the therapeutics sector, focused on developing medical treatments that are generally considered speculative in nature. The company is listed in Australia and raises capital through equity offerings to fund its ongoing operational and development activities within the life sciences market.
Technical Sentiment Signal: Sell
Current Market Cap: A$6.52M
For an in-depth examination of PER stock, go to TipRanks’ Overview page.